Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States

Fig. 2

Distribution of irAE cases among patients treated with seven FDA-approved ICIs according to the FDA dataset in the past seven years. A-C irAE cases for each ICI were divided into seven outcome groups, including died, disabled, hospitalized, life-threatening, non-serious, required intervention and other outcomes. The total percentage for each outcome group is indicated for ICIs targeting PD1, PDL1 and CTLA4 in (A), (B) and (C), respectively. D Comparison of the rate of hospitalization among patients treated with each ICI. E Proportions of serious irAEs or deaths for each FDA-approved ICI in the FDA dataset (left) and summary of statistical analysis of odds ratio (OR) for seven FDA-approved ICIs (right)

Back to article page